Single walled carbon nanotube composites for bone tissue engineering.
Ashim Gupta, Mia D Woods, Kenneth David Illingworth...
https://pubmed.ncbi.nlm.nih.gov/23629922/Actively Recruiting
Led by R3 Medical Research · Updated on 2024-09-23
120
Participants Needed
5
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety and feasibility of injecting Whartons Jelly WJ allograft directly into the knee joint of patients with knee osteoarthritis OA. This pilot study is randomized, prospective, and open-label, focusing on dose escalation without a control group. It includes patients aged 30 and older with moderate knee OA. The study aims to observe safety and possible improvements in pain and function over one year. Participants will be randomly assigned to receive one of three doses of WJ allograft in a single knee injection 2cc low dose, 3cc medium dose, or 4cc high dose. A total of 120 patients will be evenly divided among these three groups. No placebo or control group is included since the primary goal is to assess safety. The treatment is administered as a direct injection into the affected knee joint. Throughout the study, participants will undergo various assessments including blood tests measuring inflammation and organ function at baseline, 1 week, 6 weeks, 3 months, 6 months, and 1 year after treatment. They will also complete pain and functional questionnaires at regular intervals to track changes. The study includes imaging and laboratory evaluations to monitor safety, pain relief, and functional improvements during the one-year follow-up period.
CONDITIONS
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
R3 Medical Research
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Low Dose: 2cc Injection | Medium Dose: 3cc Injection | High Dose: 4cc Injection |
|---|---|---|---|
| What it is | A direct intra-articular injection of 2cc umbilical cord Wharton's jelly allograft into the knee joint. | A direct intra-articular injection of 3cc umbilical cord Wharton's jelly allograft into the knee joint. | A direct intra-articular injection of 4cc umbilical cord Wharton's jelly allograft into the knee joint. |
| Role in trial | One of three investigational dose arms to assess safety and feasibility for knee osteoarthritis. | One of three investigational dose arms to assess safety and feasibility for knee osteoarthritis. | One of three investigational dose arms to assess safety and feasibility for knee osteoarthritis. |
| Primary use | Intended to investigate the lowest dose of Wharton's jelly allograft for knee pain and osteoarthritis symptoms. | Intended to investigate a mid-range dose of Wharton's jelly allograft for knee pain and osteoarthritis symptoms. | Intended to investigate the highest dose of Wharton's jelly allograft for knee pain and osteoarthritis symptoms. |
| How it is given or performed | Single intra-articular injection of 2cc Wharton's jelly allograft into the knee under sterile conditions. | Single intra-articular injection of 3cc Wharton's jelly allograft into the knee under sterile conditions. | Single intra-articular injection of 4cc Wharton's jelly allograft into the knee under sterile conditions. |
| Evidence status | Specific clinical outcome evidence for the 2cc dose is not yet established; the trial is ongoing, and results have not been published. | Specific clinical outcome evidence for the 3cc dose is not yet established; the trial is ongoing, and results have not been published. | Specific clinical outcome evidence for the 4cc dose is not yet established; the trial is ongoing, and results have not been published. |
| Important limitations | Results for the 2cc dose are not yet available; the safety and efficacy for this cohort have not been established and only investigational outcomes are being measured. | Results for the 3cc dose are not yet available; the safety and efficacy for this cohort have not been established and only investigational outcomes are being measured. | Results for the 4cc dose are not yet available; the safety and efficacy for this cohort have not been established and only investigational outcomes are being measured. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - One-time injection with follow-up assessments over one year
Participants receive one intra-articular knee injection of Umbilical Cord Wharton's Jelly Allograft at low, medium, or high dose to evaluate safety and feasibility for knee osteoarthritis.
1 treatment visit and multiple follow-up visits over 1 year
Duration - Up to 1 year after injection
Participants are monitored for safety, pain relief, and functional improvements with scheduled assessments including laboratory tests and outcome surveys.
Visits at 24 hours, 1 week, 6 weeks, 3 months, 6 months, and 1 year post-injection
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Ashim Gupta, Mia D Woods, Kenneth David Illingworth...
https://pubmed.ncbi.nlm.nih.gov/23629922/Timothy L Kahn, Aydin Soheili, Ran Schwarzkopf
https://pubmed.ncbi.nlm.nih.gov/24600532/Ashim Gupta, Saadiq F El-Amin, Howard J Levy...
https://pubmed.ncbi.nlm.nih.gov/32054483/Joseph D Lamplot, Scott A Rodeo, Robert H Brophy
https://pubmed.ncbi.nlm.nih.gov/31038990/Mike D Van Manen, James Nace, Michael A Mont
https://pubmed.ncbi.nlm.nih.gov/23139341/Ashim Gupta, Craig Cady, Anne-Marie Fauser...
https://pubmed.ncbi.nlm.nih.gov/33316880/Bahar Dernek, Tahir Mutlu Duymus, Pinar Kursuz Koseoglu...
https://pubmed.ncbi.nlm.nih.gov/27942115/Benjamin J Main, Nicola Maffulli, Josiah A Valk...
https://pubmed.ncbi.nlm.nih.gov/34832872/Hugo C Rodriguez, Manu Gupta, Emilio Cavazos-Escobar...
https://pubmed.ncbi.nlm.nih.gov/33033884/Jack Farr, Andreas H Gomoll, Adam B Yanke...
https://pubmed.ncbi.nlm.nih.gov/31533151/R3 Medical Research
Lead Sponsor